| Literature DB >> 25807273 |
Grazziela P Figueredo1, Peer-Olaf Siebers2, Uwe Aickelin2, Amanda Whitbrook3, Jonathan M Garibaldi1.
Abstract
Advances in healthcare and in the quality of life significantly increase human life expectancy. With the aging of populations, new un-faced challenges are brought to science. The human body is naturally selected to be well-functioning until the age of reproduction to keep the species alive. However, as the lifespan extends, unseen problems due to the body deterioration emerge. There are several age-related diseases with no appropriate treatment; therefore, the complex aging phenomena needs further understanding. It is known that immunosenescence is highly correlated to the negative effects of aging. In this work we advocate the use of simulation as a tool to assist the understanding of immune aging phenomena. In particular, we are comparing system dynamics modelling and simulation (SDMS) and agent-based modelling and simulation (ABMS) for the case of age-related depletion of naive T cells in the organism. We address the following research questions: Which simulation approach is more suitable for this problem? Can these approaches be employed interchangeably? Is there any benefit of using one approach compared to the other? Results show that both simulation outcomes closely fit the observed data and existing mathematical model; and the likely contribution of each of the naive T cell repertoire maintenance method can therefore be estimated. The differences observed in the outcomes of both approaches are due to the probabilistic character of ABMS contrasted to SDMS. However, they do not interfere in the overall expected dynamics of the populations. In this case, therefore, they can be employed interchangeably, with SDMS being simpler to implement and taking less computational resources.Entities:
Mesh:
Year: 2015 PMID: 25807273 PMCID: PMC4373923 DOI: 10.1371/journal.pone.0118359
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Rate values for the mathematical model (obtained from [3]).
| rate | value(s) |
|---|---|
|
|
|
|
| 0.22, 2.1, 0.003 |
|
| 4.4 |
|
| 0 (no proliferation) or |
|
| 0 |
|
| 0.05 |
|
| 1 |
Fig 1The data set used as a look-up table for the active cells.
Fig 2The system dynamics model, functions and parameters.
Parameters from the mathematical model and their correspondents from the SD model.
| rate | correspondent |
|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| n |
|
| (Naive) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flow calculations for the naïve T cell output model.
| Stock | Flow | Expression | Flow formula | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
|
|
| |||
|
|
| ( | |||
|
|
|
| ( | ||
|
|
| ( | |||
|
|
|
| ( | ||
|
|
| ( | |||
|
|
| ( |
Fig 3The naïve T cell agent.
Agents’ parameters and behaviours for the naïve T cell output model.
| State | Parameters | Reactive behaviour | Proactive behaviour | |||
|---|---|---|---|---|---|---|
|
|
| Dies | ||||
| Is produced by thymus | ||||||
|
| Reproduces | |||||
|
|
| Dies | ||||
|
| Is produced by Naive proliferation | |||||
|
| Is produced from Memory | |||||
|
| Reproduces | |||||
|
|
| Dies | ||||
|
| Is produced from active cells | |||||
|
| Turns into Naive |
Fig 4New agent (T cell) state decision flow chart.
Simulation parameters for different scenarios.
The parameter c is only used in the first scenario, where there is no proliferation. In the other scenarios, proliferation is defined by the equation [3].
| Scenario | Description | Parameters | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
| 1 | No peripheral proliferation | 0.22 | 0.05 | 387 | 0.48 | 3.4 | 0.13 | 0 |
| 2 | No homeostatic reduction in thymic export, no homeostatic alteration of naive death rate | 2.1 | 0 | 713 | 0 | 0 | 4.4 | – |
| 3 | Homeostatic alteration of naive death rate but not thymic export | 0.003 | 0 | 392 | 0 | 4.2 | 4.4 | – |
| 4 | Homeostatic alteration of thymic export but no naive death rate | 0.005 | 0 | 378 | 2.4 | 0 | 4.4 | – |
| 5 | No restrictions | 0.005 | 0 | 378 | 2.2 | 0.13 | 4.4 | – |
The data set used for validation (obtained in [3] and [28]).
| Age |
| number of individuals |
|---|---|---|
| 0 | 5.03 | 48 |
| 1–4 | 4.93 | 53 |
| 5–9 | 4.86 | 19 |
| 10–14 | 4.86 | 19 |
| 15–19 | 4.56 | 33 |
| 20–24 | 3.88 | 26 |
| 25–29 | 3.75 | 47 |
| 30–34 | 3.61 | 65 |
| 35–39 | 3.54 | 73 |
| 40–44 | 3.52 | 52 |
| 45–49 | 3.37 | 55 |
| 50–54 | 3.17 | 16 |
The data set collected in Lorenzi et al. [29].
| Age |
| number of individuals |
|---|---|---|
| 0 | 4.85 | 2 |
| 1–4 | 5.29 | 30 |
| 5–9 | 5.05 | 33 |
| 10–14 | 4.99 | 15 |
| 15–19 | 4.56 | 5 |
| 20–24 | 4.55 | 12 |
| 25–29 | 4.55 | 9 |
| 30–34 | 4.44 | 20 |
| 35–39 | 4.23 | 15 |
| 40–44 | 4.16 | 9 |
| 45–49 | 3.82 | 16 |
| 50–54 | 4.21 | 21 |
Fig 5Data sets (collected in [3, 28] and [29]) used for validation of the naïve T cell output simulation models.
Fig 6Results for naïve T cells from the thymus.
Fig 7Results for naïve T cells from peripheral proliferation.
Fig 8Results for total T cells.
Wilcoxon test with 5% significance level comparing the results from SDMS and ABMS.
| Scenario | p |
|---|---|
| 1 | 0.8650 |
| 2 | 0.8750 |
| 3 | 0.7987 |
| 4 | 0.8408 |
| 5 | 0.9719 |